In Brief: Perclose Inc.
This article was originally published in The Gray Sheet
Perclose Inc.: Launches in Europe, Canada and Japan its second-generation two-suture Prostar Plus 10F percutaneous vascular surgical system for use in closing arterial access sites following catheterization procedures. The firm also announces completion of initial U.S. clinical trials of the system. Perclose has filed for an investigational device exemption to incorporate the device into its randomized, 500-patient STAND II clinical trial, which is comparing use of the firm's Prostar Plus 8F to standard compression ("The Gray Sheet" May 20, In Brief)...
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.